These seven clade C SHIVs were combined in equal ratios (100 TCID 50 of each of the viruses) to make a pool of viruses and were inoculated in two naïve rhesus monkeys intravenously. Infecting clones of SHIVs were isolated from the monkeys at various timepoints during the course of infection as indicated by the arrows. Clones isolated from monkey A8V032 are shown in "Red" letterings and the time point is indicated by "Red" arrow, whereas clones isolated from monkey A8V056 are shown in "Black" letterings and timepoints are shown in "black" arrows. The number of clones present in the total number of isolated clones at each timepoint is noted in parentheses next to each of the clones. Among nineteen clones isolated from monkey A8V056 at day 14 post-infection, four clones matched with SHIV KB9 C3, fourteen matched with SHIV KB9 C4 and one matched with SHIV KB9 C5 sequences. A total of seven clones of SHIV KB9 C3 were isolated from monkey A8V056 at day 49 post-infection and, at day 98 post-infection, two SHIV KB9 C3 and eight SHIV KB9 C5 clones were detected in ten isolated clones. All five clones isolated from monkey A8V032 at day 14 post-infection matched the sequence of SHIV KB9 C4. Fig. 3 . In vivo infectivity of the individual clones of SHIVs. Culture supernatants containing 1000 TCID50 of SHIV KB9 C3, SHIV KB9 C4 or SHIV KB9 C5 were used to infect two naïve rhesus monkeys each by the intravenous route. (A) Plasma viral RNA level in monkeys. The data associated with SHIV KB9 C3 are shown in red, SHIV KB9 C4 in blue and SHIV KB9 C5 in green symbols and lines. All three viruses were able to establish infection with high peak viremia of 10 6-7 RNA copies/ml, with sustained viremia up to 400 days post-infection. (B) CD4þ T lymphocyte subsets were determined by multi-channel flow cytometry for CD3, CD4, CD8, CD28, CD95, CCR5 and CCR7. Total CD4 þ T lymphocyte counts were calculated by multiplying the total lymphocyte count by the percentage of CD3 þ CD4þ T cells. CD4þ T lymphocyte counts were monitored for all six monkeys post-infection and are shown using same color scheme as in (A). No significant decline in CD4þ T lymphocyte counts was seen. Fig. 4 . Mucosal transmissibility of the SHIV KB9 C3, SHIV KB9 C4, and SHIV KB9 C5 challenge stocks. Undiluted stocks of SHIV KB9 C3 and SHIV KB9 C5 (A) SHIV KB9 C4 (B) were inoculated into naïve rhesus monkeys by the intrarectal route. Challenge stocks of all three clade C T/F SHIVs were able to establish infection in the monkeys by the mucosal route. Infections resulted in high peak viremia of 10 6-8 RNA copies/ml at 14-22 days post-infection. Persistent viremia of 10 3 RNA copies/ml was observed in the SHIV KB9 C3-infected monkey up to 130 days post-infection. For the SHIV KB9 C5-infected monkey, plasma viral RNA of 10 3 copies/ml was detected up to 330 days postinfection. For the SHIV KB9 C4-infected monkeys, viremia of 10 3 RNA copies/ml was observed up to 180 days post-infection. were inoculated into a total of eight naïve rhesus monkeys by the intra-rectal route. Monkeys inoculated with the undiluted virus stock or with, 1:2, 1:5 and 1:10 dilutions of the virus are shown in "Green", "Magenta", "Blue" and "Black" lines and symbols, respectively. One of the monkeys receiving 1:5 (monkey R550) and 1:10 (monkey R924) dilutions of the virus remained uninfected.
